港股異動 | 融信中國漲逾3% 斥資974.37萬港元回購111.1萬股
格隆匯9月30日丨融信中國(3301.HK)現報9.14港元,漲3.16%,暫成交378萬港元,最新總市值157億港元。融信中國最新公佈,9月27日公司以每股8.6-8.95港元回購111.1萬股,耗資約974.37萬港元。此外據悉,融信中國獲納入港股通(滬)名單,已於9月9日起生效。其港股通累計持倉比例自7月底的8.38%逐步上升至8月底的8.76%,及至上週五(9月27日)的9%。 融信中國曾公佈中期業績指,期內營收達266.16億元(人民幣,下同),同比增長86%;毛利潤63.61億元,同比增長52%;歸母核心淨利潤19.56億元,同比增長約26%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.